PharmAust (ASX:PAA) Institutional Ownership : 0.04% (As of May. 28, 2024)

View and export this data going back to 2001. Start your Free Trial

What is PharmAust Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PharmAust's institutional ownership is 0.04%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PharmAust's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PharmAust's Float Percentage Of Total Shares Outstanding is 0.00%.

PharmAust Institutional Ownership Historical Data

The historical data trend for PharmAust's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmAust Institutional Ownership Chart

PharmAust Historical Data

The historical data trend for PharmAust can be seen below:

	2024-02-29	2024-03-31	2024-04-30
Institutional Ownership	0.04	0.04	0.04

PharmAust Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

PharmAust (ASX:PAA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmAust Ltd (ASX:PAA) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

ECQ:Germany ECQ:Germany

Address

1 Kyle Way, Suite 116, Claremont, Perth, WA, AUS, 6010

Website

https://www.pharmaust.com

PharmAust Ltd operates as a drug discovery and development company in Australia, Switzerland, and internationally. It develops drug discovery intellectual property for the treatment of various cancers in humans and animals. The company offers Monepantel and Albendazole, which are in Phase II clinical trials for the treatment of cancer. It also provides medicinal and synthetic chemistry services on a contract basis to the drug discovery and pharmaceutical industries.